Subcutaneous bispecific T‑cell–engaging antibody (CD3×CD20) that redirects cytotoxic T cells to kill CD20+ B cells.
Bispecific monoclonal antibody that simultaneously binds CD3 on T cells and CD20 on B cells, crosslinking T cells to CD20+ malignant B cells to trigger T‑cell activation and cytotoxic killing (immune synapse formation, perforin/granzyme release, cytokine production) of the target B cells.
NO
INDIRECT
Epcoritamab binds CD3 epsilon on T cells and CD20 on B cells to recruit/activate T cells; the activated T cells kill CD20+ B cells via immune synapse formation and perforin/granzyme-mediated cytotoxicity.
Anti‑CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells, depleting CD20+ cells via ADCC, CDC, antibody-dependent phagocytosis, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC (NK cells), antibody-dependent phagocytosis (macrophages), complement-dependent cytotoxicity (CDC), and can induce apoptosis upon CD20 cross-linking.
Glycoengineered type II anti‑CD20 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases FcγRIIIa binding to enhance ADCC (and ADCP), and it triggers strong direct, largely caspase‑independent cell death, leading to depletion of CD20+ malignant B cells.
YES
DIRECT
Binds CD20 on B cells, triggering direct caspase-independent cell death and engaging Fc-gamma RIIIa–bearing effector cells (NK cells/macrophages) to mediate ADCC/ADCP, depleting CD20+ cells.
Glycoengineered type II anti‑CD20 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases FcγRIIIa binding to enhance ADCC (and ADCP), and it triggers strong direct, largely caspase‑independent cell death, leading to depletion of CD20+ malignant B cells.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages CD16a on NK cells/macrophages to drive ADCC/ADCP and direct cell death of CD20+ B cells. CD16a+ effector cells are not targeted or killed.
Glycoengineered type II anti‑CD20 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases FcγRIIIa binding to enhance ADCC (and ADCP), and it triggers strong direct, largely caspase‑independent cell death, leading to depletion of CD20+ malignant B cells.
NO
INDIRECT
CD16b is an Fc receptor on effector cells (e.g., neutrophils). Obinutuzumab targets CD20 on B cells and uses its Fc to engage Fcγ receptors (e.g., CD16) to drive ADCC/ADCP against CD20+ cells; CD16b+ cells are not the targets killed.